eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2025-09-30 18 3 2187 2201 10.13005/bpj/3246 67000 article Utkarsh Upadhyay 1 Vivek Srivastava 1 Neha Mathur 1 Somesh Thapliyal 2 Amity Institute of Pharmacy, Amity University Lucknow Campus, Lucknow, India Department of Pharmaceutical Sciences, Hemvati Nandan Bahuguna Garhwal University, Srinagar, Uttarakhand India Breast carcinoma is the world's most common cancer and the top cause of death for women among all cancers. Cancer immunotherapy has made significant clinical progress, particularly in adoptive cell transfer therapy and immune checkpoint inhibition in the treatment of breast cancer. The treatment of breast cancer has evolved a lot because of several advancements in the understanding of the pathways as well as of molecular approach. Chimeric antigen receptor target (CART), Program lethal ligand 1 & 2(PD-1/PDL-2), and the cytotoxic T-lymphocyte–associated factor 4 (CTLA-4) checkpoint inhibitors are the prime targets with positive results for the   treatment using immunotherapy. Only four drugs of this category have been approved by the FDA till now. Several vaccines are under clinical trials in mono as well as in combination therapy for the treatment of the same and their response data are summarized in this review .In this review clinical trial data on CART therapy, PD- 1/PDL-1, CTLA-4 checkpoint inhibitors, and their therapeutic approach have been explored and to provide all the treatment options available for the management of breast cancer in immunotherapy. https://biomedpharmajournal.org/vol18no3/recent-clinical-advancements-in-immunotherapy-for-the-management-of-breast-cancer/ Breast Cancer CART-Therapy CTLA-4 Immunotherapy PD-1/PDL-1 Vaccines